RNAZ Transcode Therapeutics
- 1.410
- +0.080+6.02%
- 1.370
- -0.040-2.84%
Transcode Therapeutics News
TransCode Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 536.81% HC Wainwright & Co. → $3 Reiterates Buy → Buy 04/03/2024 536.81% HC Wainwright & Co. →
TransCode Therapeutics: A Promising Oncology Investment With FDA-Backed Clinical Advancements
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial With TTX-MC138 In Patients With Advanced Solid Tumors
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial With TTX-MC138 In Patients With Advanced Solid Tumors
Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics with a Buy and maintains $3 price target.
TransCode Therapeutics Reports FY Results
Press Release: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy BOST
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positi
TransCode Therapeutics Reports Publication Of U.S. Patent Application Titled, "Nanoparticles And Template Directed RIG-I Agonist Precursor Compositions And Uses Thereof For Cancer Therapy"
TransCode Therapeutics Reports Publication Of U.S. Patent Application Titled, "Nanoparticles And Template Directed RIG-I Agonist Precursor Compositions And Uses Thereof For Cancer Therapy"
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United
Transcode Therapeutics Filed U.S. Patent Application # 20240042070: NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY
Transcode Therapeutics Filed U.S. Patent Application # 20240042070: NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY
TransCode Therapeutics Regained Compliance With Nasdaq
TransCode Therapeutics Regained Compliance With Nasdaq
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersTransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 17.2% to $0.81 during Wednesday's after-market session. Align Tech (NASDAQ:ALGN) shares increased by 13.29% to $302.86. The company'
Nasdaq Determines TransCode Therapeutics Compliance With Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that
Looking Into TransCode Therapeutics's Recent Short Interest
TransCode Therapeutics's (NYSE:RNAZ) short percent of float has risen 2201.23% since its last report. The company recently reported that it has 394 thousand shares sold short, which is 37.51% of all r
TransCode Therapeutics Collaborates With Debiopharm; Financial Terms Not Disclosed
The collaboration will explore combining TransCode's proprietary TTX delivery platform with Debiopharm's expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research
Press Release: TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the "Company"), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants.
12 Health Care Stocks Moving In Monday's After-Market Session
GainersCadrenal Therapeutics (NASDAQ:CVKD) shares moved upwards by 8.5% to $1.15 during Monday's after-market session. The market value of their outstanding shares is at $14.9 million. vTv Therapeutic
TransCode (RNAZ) Down 50% on Issue of New Common Stock
TransCode Therapeutics RNAZ announced that it is floating a secondary issue of around 5.94 million shares of its common stock to the public at an issue price of $1.22 per share, amounting to $7.5 million.
Analysis
Price Target
No Data
